Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes

Biochemical Journal

Volumn 412, Issue 2, 2008, Pages 359-366

  Zibrova, Darya ^a   Grempler, Rolf ^a   Streicher, Rüdiger ^a   Kauschke, Stefan G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Glycogen metabolism; Glycogen phosphorylase; Glycogen phosphorylase inhibitor; Glycogen synthesis; Liver glycogen targeting subunit (Gl); Type 2 diabetes

Indexed keywords

BIOSYNTHESIS; ENZYME INHIBITION; LIVER; MEDICAL PROBLEMS; METABOLISM; RATS;

DEPHOSPHORYLATION; GLYCOGEN METABOLISM; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE INHIBITORS; GLYCOGEN SYNTHESIS; LIVER GLYCOGEN TARGETING SUBUNIT; TYPE 2 DIABETES;

ENZYME ACTIVITY;

GLYCOGEN PHOSPHORYLASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DEPHOSPHORYLATION; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; RAT;

ANIMALS; CARRIER PROTEINS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; HEPATOCYTES; HUMANS; MALE; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN SUBUNITS; RATS; RATS, WISTAR;

RATTUS;

EID: 44449170938     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20071483     Document Type: Article

References (28)

1. DeFronzo, R. A. (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 131, 281-303
2. Consoli, A. (1992) Role of liver in pathophysiology of NIDDM. Diabetes Care 15, 430-441
3. DeFronzo, R. A., Bonadonna, R. C. and Ferrannini, E. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318-368
4. Edelman, S. V. (1998) Type II diabetes mellitus. Adv. Intern. Med. 43, 449-500
5. Treadway, J. L., Mendys, P. and Hoover, D. J. (2001) Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs 10, 439-454
6. Baker, D. J., Greenhaff, P. L., MacInnes, A. and Timmons, J. A. (2006) The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction. Diabetes 55, 1855-1861
7. Coakley, J. H., Wagenmakers, A. J. and Edwards, R. H. (1992) Relationship between ammonia, heart rate, and exertion in McArdle's disease. Am. J. Physiol. 262, E167-E172
8. Sahlin, K., Areskog, N. H., Haller, R. G., Henriksson, K. G., Jorfeldt, L. and Lewis, S. F. (1990) Impaired oxidative metabolism increases adenine nucleotide breakdown in McArdle's disease. J. Appl. Physiol. 69, 1231-1235
9. Armstrong, C. G., Doherty, M. J. and Cohen, P. T. (1998) Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem. J. 336, 699-704
10. Cohen, P. (2006) The twentieth century struggle to decipher insulin signalling. Nat. Rev. Mol. Cell Biol. 7, 867-873
11. Doherty, M. J., Cadefau, J., Stalmans, W., Bollen, M. and Cohen, P. T. (1998) Loss of the hepatic glycogen-binding subunit (GL) of protein phosphatase 1 underlies deficient glycogen synthesis in insulin-dependent diabetic rats and in adrenalectomized starved rats. Biochem. J. 333, 253-257
12. Moorhead, G., MacKintosh, C., Morrice, N. and Cohen, P. (1995) Purification of the hepatic glycogen-associated form of protein phosphatase-1 by microcystin-Sepharose affinity chromatography. FEBS Lett. 362, 101-105
13. Alemany, S. and Cohen, P. (1986) Phosphorylase a is an allosteric inhibitor of the glycogen and microsomal forms of rat hepatic protein phosphatase-1. FEBS Lett. 198, 194-202
14. Oikonomakos, N. G., Skamnaki, V. T., Tsitsanou, K. E., Gavalas, N. G. and Johnson, L. N. (2000) A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure 8, 575-584
15. Grempler, R., Leicht, S., Kischel, I., Eickelmann, P. and Redemann, N. (2007) Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation. FEBS Lett. 581, 5885-5890
16. Aiston, S., Green, A., Mukhtar, M. and Agius, L. (2004) Glucose 6-phosphate causes translocation of phosphorylase in hepatocytes and inactivates the enzyme synergistically with glucose. Biochem. J. 377, 195-204
17. Pautsch, A., Stadler, N., Wissdorf, O., Langkopf, E., Moreth, W. and Streicher, R. (2008) Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase. J. Biol. Chem. 283, 8913-8918
18. Kelsall, I. R., Munro, S., Hallyburton, I., Treadway, J. L. and Cohen, P. T. (2007) The hepatic PP1 glycogen-targeting subunit interaction with phosphorylase a can be blocked by C-terminal tyrosine deletion or an indole drug. FEBS Lett. 581, 4749-4753
19. Hoover, D. J., Lefkowitz-Snow, S., Burgess-Henry, J. L., Martin, W. H., Armento, S. J., Stock, I. A., McPherson, R. K., Genereux, P. E., Gibbs, E. M. and Treadway, J. L. (1998) Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem. 41, 2934-2938
20. Klabunde, T., Wendt, K. U., Kadereit, D., Brachvogel, V., Burger, H. J., Herling, A. W., Oikonomakos, N. G., Kosmopoulou, M. N., Schmoll, D., Sarubbi, E. et al. (2005) Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J. Med. Chem. 48, 6178-6193
21. Latsis, T., Andersen, B. and Agius, L. (2002) Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes. Biochem. J. 368, 309-316
22. Aiston, S., Coghlan, M. P. and Agius, L. (2003) Inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis. Eur. J. Biochem. 270, 2773-2781
23. Aiston, S., Hampson, L., Gomez-Foix, A. M., Guinovart, J. J. and Agius, L. (2001) Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. J. Biol. Chem. 276, 23858-23866
24. David, M., Petit, W. A., Laughlin, M. R., Shulman, R. G., King, J. E. and Barrett, E. J. (1990) Simultaneous synthesis and degradation of rat liver glycogen. An in vivo nuclear magnetic resonance spectroscopic study. J. Clin. Invest. 86, 612-617
25. Shulman, G. I., Rothman, D. L., Chung, Y., Rossetti, L., Petit, Jr, W. A., Barrett, E. J. and Shulman, R. G. (1988) 13C NMR studies of glycogen turnover in the perfused rat liver. J. Biol. Chem. 263, 5027-5029
26. Andersen, B. and Westergaard, N. (2002) The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors. Biochem. J. 367, 443-450
27. Gordon, N. (2003) Glycogenosis type V or McArdle's disease. Dev. Med. Child Neurol. 45, 640-644
28. Munro, S., Cuthbertson, D. J., Cunningham, J., Sales, M. and Cohen, P. T. (2002) Human skeletal muscle expresses a glycogen-targeting subunit of PP1 that is identical to the insulin-sensitive glycogen-targeting subunit G(L) of liver. Diabetes 51, 591-598